{
  "abstract": "Short bowel syndrome (SBS) is a malabsorptive condition that can be associated with intestinal failure (SBS-IF), and require long-term parenteral nutrition (PN). Prolonged PN is associated with serious complications, including liver dysfunction and catheter-related sepsis, and SBS is associated with growth impairment. Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, promotes intestinal adaptation and can reduce PN dependency. However, evidence from long-term real-world follow-up for >2 years in children is lacking.We conducted a retrospective longitudinal review of Children with SBS-IF who had started treatment with GLP-2 analogue, teduglutide 7-10 years ago. Eight patients were identified. Three children were excluded, one with a duodeno-rectal anastomosis failed to respond and stopped treatment and two others had transitioned to adult care. Collected data from electronic patient records included SBS aetiology, residual small bowel length, presence/absence of ileo-caecal valve(ICV), anthropometry (weight, height, BMI z-scores), PN characteristics (weekly volume and nights per week), plasma citrulline concentrations.Five patients (3 male, 2 female) remained under our long-term care and were reviewed after a mean treatment duration of 9 (range 8 -10) years. See table 1 below for clinical details:The mean weekly PN volume per kilogram decreased by 47%, with all patients achieving ≥20% reduction and two attaining full PN weaning. The mean number of PN nights per week decreased by 52% (−1 to −5 nights/week). Plasma citrulline levels remained stable over time (mean Δ +9 µmol/L in responders), within or above the paediatric reference range, indicating preserved mucosal function.Weight-for-age z-scores (WAZ) showed a modest overall decline, more pronounced in patients with greater baseline PN dependence. Height-for-age z-scores (HAZ) remained between −1 and −4 SDS, indicating persistent, stable growth on lower centiles. Bone age was mildly to moderately delayed, in line with stature deficit, with partial catch-up in some patients.The two patients who stopped PN have maintained enteral autonomy for 4 and 5 years. There were no unexpected adverse events.In conclusion, GLP-2 treatment was associated with sustained long-term reduction in PN requirements and no new safety concerns for up to 10 years follow up.Abstract OC15 Table 1clinical detailspatient12345Age at onset of SBSneonatePremature twin neonate 29 weeksneonateneonateneonateaetiologyIntestinal aganglionosisNecrotising enterocolitisCongenital atresiagastroschisisNecrotising enterocolitisRemaining length small intestine53 cm29 cm18 cm15 cm8 cmI-C valvenonoyesnonoColon lengthNone; ileostomyRectum onlyFull colonDistal 2/3 colon50% colonotherIntestinal mucosa inflammationAlactasia food allergiesAnastomotic ulcer - -Feeding difficultiesOn/off PNonOFFonOFFon",
  "authors": [
    {
      "affiliations": [
        "Great Ormond Street Hospital NHS Foundation Trust"
      ],
      "name": "Alessia Salatto"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital NHS Foundation Trust"
      ],
      "name": "Sophie Montgomery-Stuart"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital NHS Foundation Trust"
      ],
      "name": "Hannah Littlechild"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital NHS Foundation Trust"
      ],
      "name": "Jutta Koeglmeier"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital NHS Foundation Trust"
      ],
      "name": "Susan Hill"
    }
  ],
  "title": "OC15 Long-term evaluation of glucagon-like peptide-2, GLP-2 treatment in children with short bowel syndrome–associated intestinal failure (SBS-IF): up to 10 years follow-up",
  "uid": "d05df130-605a-54b1-b17c-ad8a9a8dbc23"
}